BioSante Pharmaceuticals announced the receipt of orphan drug designation for its melanoma cancer vaccine in the treatment of stage IIb to IV melanoma, from the FDA. Orphan drug designation, as granted by the U.S. Orphan Drug Act, is for a product to treat a rare disease or condition that affects fewer than 200,000 people in the U.S.